AZA
KERX

Arthur Zaske & Associates’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Arthur Zaske & Associates’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,103
Closed -$86K – 96
2017
Q3 		$86K Sell
12,103
-3,876
-24% -$27.9K 0.09% 85
2017
Q2 		$116K Buy
15,979
+2,597
+19% +$16.2K 0.1% 82
2017
Q1 		$82K Buy
+13,382
New +$73.3K 0.06% 77

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Arthur Zaske & Associates's KERX Position: Q4 2017 in Review

Arthur Zaske & Associates sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 12,103 shares — an estimated $86K sold.

Arthur Zaske & Associates first reported a position in KERX in Q1 2017 and held it in 3 quarters. The position peaked at $116K in Q2 2017. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • Arthur Zaske & Associates reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Arthur Zaske & Associates sold 12,103 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $86K.
  • Arthur Zaske & Associates first reported a position in Keryx Biopharmaceuticals Inc in Q1 2017 and held it in 3 quarters.
  • Arthur Zaske & Associates's Keryx Biopharmaceuticals Inc position peaked at $116K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on Arthur Zaske & Associates's 13F filing for Q4 2017, filed 14 Feb 2018.